secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0000950170-25-067495
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio reports Q1 2025 net loss $15.8M; $138.3M cash; BBI-355 data due H2 2025
--------------------------------------------------------------------------------

- Cash, cash equivalents, and short-term investments totaled $138.3M as of March 31, 2025, providing runway into 2027.
- Net loss of $15.8M for Q1 2025 versus $15.4M in Q1 2024; R&D expenses $12.1M ($13.1M Q1 2024), G&A $5.2M ($3.8M).
- BBI-355 Phase 1/2 POTENTIATE trial enrollment ongoing; preliminary clinical proof-of-concept data expected second half 2025.
- Novel Kinesin program: development candidate nomination expected mid-2025, IND filing planned for first half 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000095017025067495/0000950170-25-067495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000095017025067495/bold-20250509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-067495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer